Bone marrow transplantation is the only therapeutic option that can eliminate thalassemic disease. Early results indicated that children in class 3 Lucarelli had a much worse outcome because of high nonrejection mortality and high rejection rate. We therefore tried to investigate a nonmyeloablative stem cell transplantation (NST) approach for such a disease in order to reduce mortality and rejection. We report here the case of successful NST in a 10-year-old girl who had class 3 Lucarelli ␤-thalassemia major. The conditioning regimen consisted of busulfan, fludarabine, antilymphocyte globulin and total lymphoid irradiation. Her GVHD prophylaxis included mycophenolate mofetil and cyclosporin. The patient had full donor engraftment without acute and chronic GVHD. She is now alive and well and remains disease-free 1 year after transplant.
Bone marrow transplantation is the only therapeutic option that can eliminate thalassemic disease. Thalassemic patient categories that are prognostically significant for the outcome of marrow transplantation have been described and tested in patients younger than 17 years of age. Three classes were identified on the basis of adequate chelation as part of conventional therapy, hepatomegaly and the presence of portal fibrosis. Early results indicated that children in class 3 had a much worse outcome, with probabilities of survival, disease-free survival, and rejection of 0.61, 0.53, and 0.16, respectively. This was largely due to a major increase in nonrejection mortality. tain sufficient hemoglobin levels in post-transplant thalassemia. This should make NST an interesting approach for thalassemia.
In order to reduce nonrejection mortality among class 3 patients we wanted to investigate the NST approach for thalassemia patients in order to overcome the poor outcome in this group of patients.
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Case report
A 10-year-old girl with homozygous ␤-thalassemia (hemoglobin typing at 5 months of age; Hb F 96%) had received monthly transfusions since 5 months of age and chelation therapy with desferrioxamine since 9 years of age. Prior to each blood transfusion, her hemoglobin level was 4 to 5 g/dl. At the age of 6 years, she underwent splenectomy because of massive splenomegaly. She also had hepatomegaly. Prior to NST, a liver biopsy was performed and demonstrated hepatic fibrosis. Her ferritin level was 5684 ng/ml. We treated the girl with NST from her 4-year-old sister, who was genotypically identical to her with respect to HLA-A, B, C. She was not a carrier of any trait associated with hemoglobinopathy. The patient also received hydroxyurea 20 mg/kg daily for 3 months prior to NST.
The conditioning regimen consisted of busulfan, 2 mg/kg orally every 12 h for 2 days; fludarabine, 35 mg/m 2 intravenously daily for 5 days; antilymphocyte globulin (Fresenius) 5 mg/kg daily for five days and total lymphoid irradiation administered as a single fraction of 500 cGy, with shielding of the liver, lungs, heart, and ovaries. 5 Peripheral blood stem cells (27.9 ϫ 10 8 nucleated cells/kg, which included 10.7 ϫ 10 6 CD34 + cells/kg) were transfused on day 0. Prophylaxis against acute graft-versus-host disease consisted of cyclosporin (at a dose adequate to maintain a level a more than 200 ng/ml until day 100 and then tapered) and mycophenolate mofetil (which was discontinued on day 45).
Other than fever caused by the antilymphocyte globulin, there were no toxic effects related to the regimen. Myelosuppression was transient; the nadir of the absolute neutrophil count was 0.8 ϫ 10 9 /l and the nadir of the platelet count was 6 ϫ 10 9 /l. The patient required only two platelet transfusions and two packed red cell transfusions after NST. Chimerism was evaluated by assay of fluorescently labeled short tandem repeats in genomic DNA. The proportion of donor cells in the recipient's blood was 100% on day 23. The patient did not have acute graft-versushost disease.
One year after NST, the patient had no clinical features of thalassemia and chronic graft-versus-host disease. The hemoglobin level was 12 g/dl. The result of hemoglobin typing was Hb A 95%, F 3% and A 2 2%. The chimerism study still showed 100% of donor cells in the recipient's blood.
Discussion
High nonrejection mortality and graft failure secondary to rejection are common obstacles to successful marrow transplantation especially in class 2 and 3 thalassemia patients. 1 Gaziev et al 6 reported that hydroxyurea, azathioprine and fludarabine prior to transplant may contribute to the success of second marrow transplant for graft failure in patients with class 3 thalassemia. They suggested that the success of second marrow transplant depends in part on increased immune suppression in the preparative regimen prior to second marrow transplant compared to that used for the first transplant. We therefore suggest that hydroxyurea prior to transplant may contribute in success of NST in this patient. This may be due to an increased immune suppression from hydroxyurea administration prior to NST. The other mechanism that reduces rejection is a large number of stem cells. Therefore, both hydroxyurea administration prior to NST and a large number of stem cells could have reduced the rejection in this patient.
NST can avoid the cytokine storm. 7 This can reduce the toxicity from the transplant procedure and contribute to reducing nonrejection mortality. The use of the NST regimen permits engraftment of donor stem cells by creating marrow space through the graft-versus-host effect, not by myeloablative chemotherapy or radiation therapy. The technique of NST has been used and reported for many diseases, mostly leukemia. Engraftment rates and complications reported in the literature are very impressive. 3, 4 Krishnamurti et al 5 reported successful NST in sickle cell disease which is an abnormal hemoglobinopathy like thalassemia. We also demonstrated in our patient that NST can be well tolerated, lead to stable engraftment, and ameliorate severe class 3 thalassemia. Furthermore, this patient is now alive and well and remains disease-free 1 year after transplant without acute or chronic graft-versus-host disease. This case report could be used as a proof of principle that NST is feasible in such a patient, although its definitive role will have to be proved in a larger case series.
